We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+3.02%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$1.63B
AUM Growth
-$156M
Cap. Flow
-$162M
Cap. Flow %
-9.89%
Top 10 Hldgs %
31.09%
Holding
143
New
4
Increased
33
Reduced
15
Closed
14

Top Buys

Rank Stock Value
1
FSLR icon
First Solar
FSLR
+$24.8M
2
ARW icon
Arrow Electronics
ARW
+$18.7M
3
WVE icon
Wave Life Sciences
WVE
+$5.92M
4
HASI icon
Hannon Armstrong Sustainable Infrastructure Capital
HASI
+$2.87M
5
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$2.75M

Top Sells

Rank Stock Value
1
RHT
Red Hat Inc
RHT
+$46.3M
2
QLIK
QLIK TECHNOLOGIES INC COM STK (DE)
QLIK
+$29.1M
3
PANW icon
Palo Alto Networks
PANW
+$19.2M
4
MDVN
MEDIVATION, INC.
MDVN
+$18.9M
5
IMPV
Imperva, Inc.
IMPV
+$16.3M

Sector Composition

Rank Sector Weight
1 Healthcare 31.3%
2 Technology 24.56%
3 Consumer Discretionary 12.61%
4 Industrials 7.43%
5 Utilities 5.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTA icon
76
Prothena Corp
PRTA
$440M
$4.2M 0.26%
120,000
– –
AGTC
77
DELISTED
Applied Genetic Technologies Corporation
AGTC
$3.94M 0.24%
279,100
– –
DVAX
78
DELISTED
Dynavax Technologies
DVAX
$3.65M 0.22%
250,000
– –
JUNO
79
DELISTED
Juno Therapeutics, Inc.
JUNO
$3.46M 0.21%
90,000
– –
VYGR icon
80
Voyager Therapeutics
VYGR
$189M
$3.3M 0.2%
300,000
– –
TGTX icon
81
TG Therapeutics
TGTX
$8.19B
$3.26M 0.2%
537,600
– –
INCY icon
82
Incyte
INCY
$24.9B
$3.2M 0.2%
40,000
– –
CEMP
83
DELISTED
Cempra, Inc.
CEMP
$3.05M 0.19%
184,900
– –
RGEN icon
84
Repligen
RGEN
$7.03B
$3.01M 0.18%
110,000
– –
VRTX icon
85
Vertex Pharmaceuticals
VRTX
$122B
$2.98M 0.18%
34,600
– –
LKFT
86
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$2.88M 0.18%
52,000
– –
NTUS
87
DELISTED
Natus Medical Inc
NTUS
$2.83M 0.17%
75,000
– –
EPZM
88
DELISTED
Epizyme, Inc
EPZM
$2.82M 0.17%
275,000
– –
GBT
89
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.74M 0.17%
165,000
– –
SYRS
90
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.72M 0.17%
+15,000
New +$2.72M
CDTX
91
DELISTED
Cidara Therapeutics
CDTX
$2.72M 0.17%
13,200
– –
TTPH
92
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$2.58M 0.16%
+30,000
New +$2.75M
ATRC icon
93
AtriCure
ATRC
$2.04B
$2.54M 0.16%
180,000
– –
CHRS icon
94
Coherus Oncology
CHRS
$227M
$2.45M 0.15%
145,000
– –
KA
95
DELISTED
Kineta, Inc. Common Stock
KA
$2.43M 0.15%
1,429
– –
OMED
96
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$2.34M 0.14%
190,000
– –
TCON
97
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$2.27M 0.14%
2,589
– –
TNDM icon
98
Tandem Diabetes Care
TNDM
$1.3B
$2.07M 0.13%
27,500
+11,820
+75% +$951K
ARAY icon
99
Accuray
ARAY
$33.9M
$1.59M 0.1%
306,200
– –
CTMX icon
100
CytomX Therapeutics
CTMX
$714M
$1.53M 0.09%
150,000
– –
2 3
4
5 6

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q2 2016 Portfolio in Review

As of Q2 2016, Eventide Asset Management held 143 positions worth $1.63B, down 8.7% from $1.79B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Eventide Asset Management withdrew a net $162M in Q2 2016, closing 14 positions and reducing 15 holdings. Its most notable exit was Red Hat Inc, an estimated $46.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 29% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Eventide Asset Management opened a new position in Arrow Electronics worth $18.3M.

  • Eventide Asset Management's largest Q2 2016 buy was Arrow Electronics: 295,000 shares worth $18.3M.
  • Eventide Asset Management added most to First Solar in Q2 2016, an estimated $24.8M increase.
  • Eventide Asset Management's biggest Q2 2016 reduction was Palo Alto Networks, cutting an estimated $19.2M.
  • Eventide Asset Management fully exited Red Hat Inc in Q2 2016, selling an estimated $46.3M.
  • Eventide Asset Management's ten largest holdings make up 31% of its $1.63B portfolio in Q2 2016.
  • Eventide Asset Management opened 4 new positions and closed 14 in Q2 2016.
  • Eventide Asset Management's portfolio value fell 8.7% quarter-over-quarter to $1.63B.

Based on Eventide Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.